141 related articles for article (PubMed ID: 32131978)
41. Exosomal onco-miRs from serum of patients with adenocarcinoma of the esophagus: comparison of miRNA profiles of exosomes and matching tumor.
Warnecke-Eberz U; Chon SH; Hölscher AH; Drebber U; Bollschweiler E
Tumour Biol; 2015 Jun; 36(6):4643-53. PubMed ID: 25631748
[TBL] [Abstract][Full Text] [Related]
42. Serum microRNA array analysis identifies miR-140-3p, miR-33b-3p and miR-671-3p as potential osteoarthritis biomarkers involved in metabolic processes.
Ntoumou E; Tzetis M; Braoudaki M; Lambrou G; Poulou M; Malizos K; Stefanou N; Anastasopoulou L; Tsezou A
Clin Epigenetics; 2017; 9():127. PubMed ID: 29255496
[TBL] [Abstract][Full Text] [Related]
43. miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus.
Smith CM; Watson DI; Leong MP; Mayne GC; Michael MZ; Wijnhoven BP; Hussey DJ
World J Gastroenterol; 2011 Feb; 17(8):1036-44. PubMed ID: 21448356
[TBL] [Abstract][Full Text] [Related]
44. Critical reappraisal of current surveillance strategies for Barrett's esophagus: analysis of a large German Barrett's database.
von Rahden BH; Stein HJ; Weber A; Vieth M; Stolte M; Rösch T; Schmid RM; Sarbia M; Meining A
Dis Esophagus; 2008; 21(8):685-9. PubMed ID: 18847456
[TBL] [Abstract][Full Text] [Related]
45. Surveillance in Barrett's esophagus: an audit of practice.
Ajumobi A; Bahjri K; Jackson C; Griffin R
Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
[TBL] [Abstract][Full Text] [Related]
46. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus.
Incarbone R; Bonavina L; Saino G; Bona D; Peracchia A
Surg Endosc; 2002 Feb; 16(2):263-6. PubMed ID: 11967675
[TBL] [Abstract][Full Text] [Related]
47. KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus.
Gossner L; May A; Stolte M; Seitz G; Hahn EG; Ell C
Gastrointest Endosc; 1999 Jan; 49(1):8-12. PubMed ID: 9869716
[TBL] [Abstract][Full Text] [Related]
48. Liver-intestine-cadherin is a sensitive marker of intestinal differentiation during Barrett's carcinogenesis.
Mokrowiecka A; Zonnur S; Veits L; Musial J; Kordek R; Lochowski M; Kozak J; Malecka-Panas E; Vieth M; Hartmann A
Dig Dis Sci; 2013 Mar; 58(3):699-705. PubMed ID: 23053896
[TBL] [Abstract][Full Text] [Related]
49. Predictors of dysplastic and neoplastic progression of Barrett’s esophagus.
Alnasser S; Agnihotram R; Martel M; Mayrand S; Franco E; Ferri L
Can J Surg; 2019 Apr; 62(2):93-99. PubMed ID: 30907564
[TBL] [Abstract][Full Text] [Related]
50. Comparison of six immunohistochemical markers for the histologic diagnosis of neoplasia in Barrett's esophagus.
Weimann A; Rieger A; Zimmermann M; Gross M; Hoffmann P; Slevogt H; Morawietz L
Virchows Arch; 2010 Nov; 457(5):537-45. PubMed ID: 20844891
[TBL] [Abstract][Full Text] [Related]
51. A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence.
Ahmad J; Arthur K; Maxwell P; Kennedy A; Johnston BT; Murray L; McManus DT
Dis Esophagus; 2015 Apr; 28(3):276-82. PubMed ID: 24612412
[TBL] [Abstract][Full Text] [Related]
52. Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma.
Ibuki Y; Nishiyama Y; Tsutani Y; Emi M; Hamai Y; Okada M; Tahara H
PLoS One; 2020; 15(4):e0231116. PubMed ID: 32251457
[TBL] [Abstract][Full Text] [Related]
53. MicroRNA expression differentiates squamous epithelium from Barrett's esophagus and esophageal cancer.
Garman KS; Owzar K; Hauser ER; Westfall K; Anderson BR; Souza RF; Diehl AM; Provenzale D; Shaheen NJ
Dig Dis Sci; 2013 Nov; 58(11):3178-88. PubMed ID: 23925817
[TBL] [Abstract][Full Text] [Related]
54. Validation of miR-1228-3p as Housekeeping for MicroRNA Analysis in Liquid Biopsies from Colorectal Cancer Patients.
Duran-Sanchon S; Vila-Navarro E; Marcuello M; Lozano JJ; Muñoz J; Cubiella J; Diez MS; Bujanda L; Lanas A; Jover R; Hernández V; Quintero E; Herreros-Villanueva M; Martín AC; Pérez-Palacios R; Arroyo R; Castells A; Gironella M
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31877644
[TBL] [Abstract][Full Text] [Related]
55. MicroRNA expression profile in serum reveals novel diagnostic biomarkers for endometrial cancer.
Fan X; Zou X; Liu C; Cheng W; Zhang S; Geng X; Zhu W
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34076696
[TBL] [Abstract][Full Text] [Related]
56. Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients.
Kumar S; Sharawat SK; Ali A; Gaur V; Malik PS; Kumar S; Mohan A; Guleria R
Curr Probl Cancer; 2020 Aug; 44(4):100540. PubMed ID: 32007320
[TBL] [Abstract][Full Text] [Related]
57. Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.
Rudolph RE; Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ
J Natl Cancer Inst; 2003 May; 95(10):750-7. PubMed ID: 12759393
[TBL] [Abstract][Full Text] [Related]
58. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients.
Peters JH; Clark GW; Ireland AP; Chandrasoma P; Smyrk TC; DeMeester TR
J Thorac Cardiovasc Surg; 1994 Nov; 108(5):813-21; discussion 821-2. PubMed ID: 7967662
[TBL] [Abstract][Full Text] [Related]
59. A Systematic Review of Esophageal MicroRNA Markers for Diagnosis and Monitoring of Barrett's Esophagus.
Mallick R; Patnaik SK; Wani S; Bansal A
Dig Dis Sci; 2016 Apr; 61(4):1039-50. PubMed ID: 26572780
[TBL] [Abstract][Full Text] [Related]
60. Circulating miRNAs: Potential diagnostic role for coronavirus disease 2019 (COVID-19).
Fayyad-Kazan M; Makki R; Skafi N; El Homsi M; Hamade A; El Majzoub R; Hamade E; Fayyad-Kazan H; Badran B
Infect Genet Evol; 2021 Oct; 94():105020. PubMed ID: 34343725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
